Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones

Human Reproduction

Volumn 29, Issue 12, 2014, Pages 2844-2851

  Aschim, E L ^a   Oldenburg, J ^b   Kristiansen, W ^a   Giwercman, A ^c   Witczak, O ^a   Fossa S D ^b   Haugen, T B ^a  

^a OSLO METROPOLITAN UNIVERSITY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY   (Sweden)

Author keywords

long term; polymorphism; sex hormones; testicular cancer; treatment

Indexed keywords

ANDROGEN RECEPTOR; CISPLATIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; GENE INSERTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOASSAY; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL; WILD TYPE; BLOOD; GENETICS; NEOPLASM; SURVIVOR; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CROSS-SECTIONAL STUDIES; GENOTYPE; HUMANS; LUTEINIZING HORMONE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, LH; SURVIVORS; TESTICULAR NEOPLASMS; TESTOSTERONE;

EID: 84929643523     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu274     Document Type: Article

References (26)

1. Allen NE, Reichardt JK, Nguyen H, Key TJ. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol Biomarkers Prev. 2003; 12: 578-581
2. Aschim EL, Nordenskjöld A, Giwercman A, Lundin KB, Ruhayel Y, Haugen TB, Grotmol T, Giwercman YL. Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene. J Clin Endocrinol Metab. 2004; 89: 5105-5109
3. Bandak M, Aksglaede L, Juul A, Rørth M, Daugaard G. The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer. Eur J Cancer. 2011; 47: 2585-2591
4. Ding D, Xu L, Menon M, Reddy GP, Barrack ER. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate. 2005; 62: 133-139
5. Eberhard J, Ståhl O, Giwercman Y, Cwikiel M, Cavallin-Ståhl E, Lundin KB, Flodgren P, Giwercman A. Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study. Hum Reprod. 2004; 19: 1418-1425
6. Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE, Moller H. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. Br Med J. 2000; 321: 789-792
7. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol. 1998; 160: 1353-1357
8. Hayes VM, Severi G, Padilla EJ, Morris HA, Tilley WD, Southey MC, English DR, Sutherland RL, Hopper JL, Boyle P, et al. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levelsand androgenetic alopecia. Int J Cancer2007; 120: 776-780
9. Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005; 93: 200-207
10. Kristiansen W, Aschim EL, Andersen JM, Witczak O, Fosså SD, Haugen TB. Variations in testosterone pathway genes and susceptibility to testicular cancer in Norwegian men. Int J Androl. 2012; 35: 819-827
11. Kuhn JM, Rieu M, Laudat MH, Forest MG, Pugeat M, Bricaire H, Luton JP. Effects of 10 days administration of percutaneous dihydrotestosterone on the pituitary-Testicular axis in normal men. J Clin Endocrinol Metab. 1984; 58: 231-235
12. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991; 352: 77-79
13. Lubahn DB, Tan JA, Quarmby VE, Sar M, Joseph DR, French FS, Wilson EM. Structural analysis of the human and rat androgen receptors and expression in male reproductive tract tissues. Ann N Y Acad Sci. 1989; 564: 48-56
14. Lundin KB, Giwercman A, Dizeyi N, Giwercman YL. Functional in vitro characterisation of the androgen receptor GGN polymorphism. Mol Cell Endocrinol. 2007; 264: 184-187
15. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res. 1997; 57: 1020-1022
16. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 1999; 354: 975-978
17. Nenonen H, Björk C, Skjaerpe P-A, Giwercman A, Rylander L, Svartberg J, Giwercman YL. CAG repeat number is not inversely associated with androgen receptor activity in vitro. Mol Hum Reprod. 2010; 16: 153-157
18. Nord C, Bjøro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E, Fosså SD. Gonadal hormones in long-Term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. 2003; 44: 322-328
19. Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24(Suppl 6): vi125-vi132
20. Piersma D, Berns EM, Verhoef-Post M, Uitterlinden AG, Braakman I, Pols HA, Themmen AP. A common polymorphism renders the luteinizing hormone receptor protein more active by improving signal peptide function and predicts adverse outcome in breast cancer patients. J Clin Endocrinol Metab. 2006; 91: 1470-1476
21. Piersma D, Verhoef-Post M, Look MP, Uitterlinden AG, Pols HA, Berns EM, Themmen AP. Polymorphic variations in Exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer. Mol Cell Endocrinol. 2007; 276: 63-70
22. Santen RJ. Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men? J Clin Invest. 1975; 56: 1555-1563
23. Schatzl G, Madersbacher S, Gsur A, Preyer M, Haidinger G, Haitel A, Vutuc C, Micksche M, Marberger M. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate. 2002; 52: 130-138
24. Simoni M, Tuttelmann F, Michel C, Bockenfeld Y, Nieschlag E, Gromoll J. Polymorphisms of the luteinizing hormone?chorionic gonadotropin receptor gene: association with maldescended testes and male infertility. Pharmacogenet Genomics. 2008; 18: 193-200
25. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-Activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab. 1997; 82: 3777-3782
26. Veldhuis JD, Urban RJ, Dufau ML. Evidence that androgen negative feedback regulates hypothalamic gonadotropin-releasing hormone impulse strength and the burst-like secretion of biologically active luteinizing hormone in men. J Clin Endocrinol Metab. 1992; 74: 1227-1235